CN104758309B - The purposes of raspberry polysaccharide for reducing blood sugar - Google Patents
The purposes of raspberry polysaccharide for reducing blood sugar Download PDFInfo
- Publication number
- CN104758309B CN104758309B CN201510169399.0A CN201510169399A CN104758309B CN 104758309 B CN104758309 B CN 104758309B CN 201510169399 A CN201510169399 A CN 201510169399A CN 104758309 B CN104758309 B CN 104758309B
- Authority
- CN
- China
- Prior art keywords
- raspberry
- polysaccharide
- food
- purposes according
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides purposes of the raspberry polysaccharide in hypoglycemic medicine, health products or food is prepared.Present invention research finds that raspberry polysaccharide has good hypoglycemic and hypolipemic function, and toxic side effect is small, has significant social value and market value.
Description
Technical field
The invention belongs to field of health care products, and in particular to purposes of the raspberry polysaccharide in hypoglycemic drug is prepared.
Technical background
According to statistics, the number of patients of China's diabetes has reached 92,400,000 at present, occupies (Yang W, et first of the whole world
Al.N Engl J Med, 2010,362 (12)：1090-1101).Up to 173,400,000,000 yuan every year of diabetes mellitus in China medical expense, sugar
Urinate disease caused by direct medical expenses accounted for Chinese medical total expenses 13% (Alcorn T, et al.Lancet,
2012,379 (9833)：2227-2228).As can be seen here, diabetes not only seriously endanger the health of the people, and are national band
Carry out heavy financial burden.Thus, preventing and treating diabetes are very urgent.
Raspberry (Rubus idaeus L.) also known as Rubus corchorifolius, raspberry, raspberry etc., belong to rose family rubus.Raspberry master
Northern Hemisphere temperate zone and frigid zone are distributed in, its fruit sweet slightly sour to starch small aggregate fruit more.Raspberry contains polysaccharide, organic acid, Huang
The various active composition such as ketone, anthocyanidin, polyphenol, vitamin, mineral element, volatile oil, tannin, have high nutritive value and
Medical care effect, it is described as " gold fruit ".
It yet there are no using raspberry polysaccharide for reducing blood sugar or treat the report of diabetes.
The content of the invention
It is an object of the invention to provide the new application of raspberry polysaccharide.
Specifically, the purposes the invention provides raspberry polysaccharide in hypoglycemic medicine, health products or food is prepared.
Further, the medicine, health products or food are prevention or medicine, the health care for the treatment of I types or type ii diabetes
Product or food.
Further, the medicine, health products or food be improve the medicine of dyslipidemia in diabetes, health products or
Food.
Further, the medicine, health products or food are to reduce diabetic TC, TG and LDL level, are improved
Medicine, health products or food horizontal HDL.
Wherein, the medicine, health products or food are peroral dosage form.
Further, the peroral dosage form is selected from tablet, capsule, pill, granule, powder, extract or oral liquid.
Wherein, in the raspberry polysaccharide, purity of polysaccharide is more than 50%；Further, purity of polysaccharide is more than 80%；More
Further, purity of polysaccharide is more than 85%；Preferably, purity of polysaccharide is 85~95%w/w, such as moderate purity of the present invention be 90~
92%.Above-mentioned purity is determined using Phenol-sulphate acid method.
Wherein, the raspberry polysaccharide is prepared using water extraction and alcohol precipitation method.
Further, the water extraction and alcohol precipitation method concrete operations are as follows：
Take dry raspberry, after petroleum ether or ether defatting, extracted, filtered with 75%~more than 95%v/v of concentration ethanol, filter
Slag extracting in water, after water intaking extract concentration, add ethanol to alcohol content to reach 75%~85%, cooling, stand, take the solid content to be
Raspberry polysaccharide.
Wherein, remove seed or non-remove seed before raspberry extraction.
Wherein, during alcohol precipitation, ethanol to alcohol content is added to reach 75%.
Wherein, the raspberry is the fruit of rose family rubus plant.
Further, the raspberry is selected from raspberry or black raspberry, selects to use in an embodiment of the invention
Raspberry.
Present invention research finds that raspberry polysaccharide has good hypoglycemic and hypolipemic function, and toxic side effect is small, has
Significant social value and market value.
Brief description of the drawings：
The raspberry polysaccharide of accompanying drawing 1 causes the influence of diabetes rat body weight to STZ；
The raspberry polysaccharide of accompanying drawing 2 causes the influence of blood glucose in diabetic rats to STZ；
Embodiment
The raspberry polysaccharide used in the specific embodiment of the invention is prepared into using conventional Polyose extraction, way of purification
Arrive, concrete operations are as follows in the present invention：
It is prepared by raspberry polysaccharide：Dry raspberry is taken, after crushing remove seed, adds 5 times of petroleum ethers (60~90 DEG C of boiling range) degreasing, eliminates stone
75%~95% ethanol is added after oily ether in 60 DEG C of backflows, the filter residue after filtering is added into 10 times of pure water ultrasonic extraction (power
60W, temperature：80 DEG C, processing time：100min), centrifuging and taking supernatant, filter residue are extracted twice, merging filtrate, subtracted again by old terms
Pressure is concentrated into the 1/4 of original volume, adds 95% ethanol, solution alcohol content is reached 75%v/v, and 24h, filtering are stood in 4 degrees Celsius
Filter residue is collected, filter residue dries to obtain raspberry polysaccharide.
After measured, the raspberry polysaccharide yield that prepared by the present invention is 10.4%~11.6%, detects to obtain through Phenol-sulphate acid method
Purity of polysaccharide is 90.8%~91.2%.
Polysaccharide dosage used is in terms of polysaccharide in various embodiments of the present invention.
Embodiment 1
The present invention evaluates raspberry polyoses capsule main component using the rat diabetes model of streptozotocin (STZ) induction
The effect of the hypoglycemic and reducing blood lipid of raspberry polysaccharide.
It is as follows that model establishes process：Rat tail vein takes blood to survey blood glucose before modeling, weighs.Fasting afterwards 12 hours,
Under rat limosis state (pH4.2 0.1mol/L citrate is dissolved in by 60mg/kg concentration disposable celiac injection STZ
Buffer solution, the matching while using under the conditions of lucifuge).96 hours rear molding venous blood samplings survey blood glucose, and blood glucose value >=16.7mmol/L's is
Think Glycemia Decline success.The successful rat of modeling is randomly divided into 5 groups, every group 10, be model group, positive control respectively
Group, raspberry polysaccharide low dose group, raspberry polysaccharide middle dosage combination raspberry polysaccharide high dose group.It is another to take 10 to make with batch healthy rat
For Normal group.The rat packet same day weighs and gastric infusion, dosage are as follows：Normal group：Pure water；Model
Group：Pure water；Positive drug group：Glibenclamide Tablets 20mg/kg；Basic, normal, high group of dosage of raspberry polysaccharide be respectively：75mg/kg、
150mg/kg、300mg/kg.Successive administration 28 days, every 7 days measurement blood glucose are simultaneously weighed.
(1) raspberry polysaccharide causes the influence of the basic sign of diabetes rat to STZ
The raspberry polysaccharide of table 1. causes the influence of diabetes rat body weight to STZ
*P ＜ 0.05vs model groups；**P ＜ 0.01vs model groups；##P ＜ 0.01vs normal groups
Such as table 1 and Fig. 1, after modeling the body weight of each group diabetes rat be remarkably decreased compared with normal rat pole (##P ＜
0.01vs normal groups), bedding and padding meet the basic sign of diabetes compared with the humidity of normal rat.The hair color of normal rats has light
Pool, bedding and padding are dried, body weight steady-state growth.The hair color of model group rats is withered, slight depilation, and bedding and padding are moist, increases body with the time
Decline again obvious.The hair color of each administration group rat is good compared with model group, and bedding and padding moisture conditions have mitigated compared with model group, with administration when
Though increasing average weight between has certain decline, and downward trend is gentler than model group, wherein positive controls rat last time
The body weight of measurement compared with model group have significant difference (*P ＜ 0.05vs model groups), each dosage group rat last time of raspberry polysaccharide
The body weight of measurement compared with model group have pole significant difference (*P ＜ 0.05vs model groups).Compared with positive drug glibenclamide, raspberry
Polysaccharide can more efficiently prevent from the mitigation of diabetes rat body weight.
(2) raspberry polysaccharide causes the influence of blood glucose in diabetic rats to STZ
The raspberry polysaccharide of table 2. causes the influence of blood glucose in diabetic rats to STZ
**P ＜ 0.01vs model groups；##P ＜ 0.01vs normal groups
As shown in table 2 and Fig. 2, after modeling, the blood glucose of normal rats without significant change, each group blood glucose in diabetic rats compared with
Normal rat extremely significantly rise (##P ＜ 0.01vs normal groups) treatment after, the blood glucose of each administration group rat has pole compared with model group
Conspicuousness decline (**P ＜ 0.01vs model groups), and the hypoglycemic effect of raspberry polysaccharide is in dose dependent.The high agent of raspberry polysaccharide
The average blood sugar value of amount group rat last time measurement is 17.84 ± 1.41mmol/L, than positive controls rat last time
The average blood sugar 18.87 ± 2.22 of measurement is also low.
(3) raspberry polysaccharide causes T-CHOL (TC), triglycerides (TG), high density fat in diabetes rat serum to STZ
The influence of albumen (HDL) and low-density lipoprotein (LDL)
Test the 28th day, after rats by intraperitoneal injection chloraldurate solution general anesthesia, separate arteria carotis communis and be intubated collection
Blood.3000r/min is centrifuged 10 minutes and is obtained serum sample after blood clotting.
The raspberry polysaccharide of table 3. causes the influence of diabetes rat blood fat to STZ
**P ＜ 0.01vs model groups；##P ＜ 0.01vs normal groups
As shown in table 3, compared with normal group, the extremely significant increase of TC, TG and LDL in model group rats serum, HDL
Extremely significantly decline (##P ＜ 0.01vs normal groups).After treatment, compared with model group, TC in each treatment group's rat blood serum,
TG and LDL is extremely significant to be declined, HDL extremely significantly increases (**P ＜ 0.01vs model groups).Wherein, the reducing blood lipid of raspberry polysaccharide
Effect strengthen with the increase of dosage.The lipid-lowering effect of the middle and high dosage group of raspberry polysaccharide is even better than positive control drug lattice
Arrange this urea piece.
Claims (15)
1. purposes of the raspberry polysaccharide in hypoglycemic medicine, health products or food is prepared.
2. purposes according to claim 1, it is characterised in that：The medicine, health products or food are prevention or treatment I types
Or medicine, health products or the food of type ii diabetes.
3. purposes according to claim 1 or 2, it is characterised in that：The medicine, health products or food are to improve diabetes
Patients with lipid abnormal medicine, health products or food.
4. purposes according to claim 1 or 2, it is characterised in that：The medicine, health products or food are to reduce diabetes
Patient TC, TG and LDL are horizontal, improve HDL horizontal medicine, health products or food.
5. purposes according to claim 1 or 2, it is characterised in that：The medicine, health products or food are peroral dosage form.
6. purposes according to claim 5, it is characterised in that：The peroral dosage form be selected from tablet, capsule, pill,
Granula, powder, extract or oral liquid.
7. purposes according to claim 1, it is characterised in that：In the raspberry polysaccharide, purity of polysaccharide is more than 50%.
8. purposes according to claim 7, it is characterised in that：Purity of polysaccharide is more than 80%.
9. purposes according to claim 8, it is characterised in that：Purity of polysaccharide is more than 85%.
10. purposes according to claim 9, it is characterised in that：Purity of polysaccharide is 85~95%w/w.
11. according to the purposes described in any one of claim 1,2,7,8,9,10, it is characterised in that：The raspberry polysaccharide uses
Water extraction and alcohol precipitation method is prepared.
12. purposes according to claim 11, it is characterised in that：The water extraction and alcohol precipitation method concrete operations are as follows：
Take dry raspberry, after petroleum ether or ether defatting, extracted with 75%~95%v/v of concentration ethanol, filtering, filter residue adds water extraction
Take, after water intaking extract concentration, add ethanol to alcohol content to reach 75%~85%, cooling, stand, it is that raspberry is more to take solid content
Sugar.
13. purposes according to claim 11, it is characterised in that：Remove seed or non-remove seed before raspberry extraction.
14. according to the purposes described in any one of claim 1,2,7,8,9,10, it is characterised in that：The raspberry is the rose family
The fruit of rubus.
15. purposes according to claim 14, it is characterised in that：The raspberry is selected from raspberry or black raspberry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510169399.0A CN104758309B (en) | 2015-04-04 | 2015-04-04 | The purposes of raspberry polysaccharide for reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510169399.0A CN104758309B (en) | 2015-04-04 | 2015-04-04 | The purposes of raspberry polysaccharide for reducing blood sugar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104758309A CN104758309A (en) | 2015-07-08 |
| CN104758309B true CN104758309B (en) | 2018-02-27 |
Family
ID=53640639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510169399.0A Active CN104758309B (en) | 2015-04-04 | 2015-04-04 | The purposes of raspberry polysaccharide for reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758309B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940427B (en) * | 2015-07-20 | 2020-03-31 | 德令哈林生生物科技开发有限公司 | Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof |
| CN111227253A (en) * | 2020-01-20 | 2020-06-05 | 江苏惠田科技开发有限公司 | Blackberry polysaccharide composite breakfast powder and preparation method thereof |
| CN112521521B (en) * | 2020-12-09 | 2021-11-05 | 青海大学 | Polysaccharide SM-W and anti-tumor product prepared from same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788755A (en) * | 2004-12-14 | 2006-06-21 | 北京市农林科学院 | Framberry leaf extract effective part and its composition and uses |
-
2015
- 2015-04-04 CN CN201510169399.0A patent/CN104758309B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788755A (en) * | 2004-12-14 | 2006-06-21 | 北京市农林科学院 | Framberry leaf extract effective part and its composition and uses |
Non-Patent Citations (4)
| Title |
|---|
| 悬钩子属植物生物学作用研究进展;韩加等;《中国野生植物资源》;20090430;第28卷(第02期);1-4,49 * |
| 树莓液对糖尿病模型大鼠血糖、胰岛素水平影响的实验研究;王敏等;《中医药信息》;20021231;第19卷(第06期);57 * |
| 粗叶悬钩子根部提取物对急性肝损伤大鼠TNF-α IL-1β IL-6的影响;洪振丰等;《中华中医药学刊》;20070630;第25卷(第06期);1137-1138 * |
| 覆盆子多糖提取、结构分析及自由基清除作用研究;刘明学等;《食品科技》;20091231;第34卷(第07期);163-167 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104758309A (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101501433B1 (en) | A composition for prevention and treatment of non-alcoholic fatty liver disease | |
| CN107412341A (en) | A kind of hypoglycemic formula containing blue or green money willow and preparation method thereof | |
| CN104383315A (en) | Chinese herbal medicinal composition for protecting liver and sobering and drink containing Chinese herbal medicinal composition | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| CN104284601B (en) | Secrete for promoting insulin-like growth factor and the white radix-polygoni multiflori extract of bone growth and Radix Dipsaci extract and manufacture method thereof | |
| CN101518595A (en) | Medical composition with functions of lowering lipid, reducing fat and oxidation resistance and preparation method thereof | |
| CN109985086B (en) | Cyclocarya paliurus leaf instant powder and preparation method thereof | |
| CN104027494B (en) | A kind of Chinese medicine composition with anti-aging and health-care efficacy | |
| KR101501233B1 (en) | Pharmaceutical composition or health food containing black tea ethanol solution extracts which is effective for reducing body weight and body fats or preventing or treating lipid related metabolic disease | |
| CN103766901A (en) | Application of andrographolide C to preparation of weight-losing food or medicine | |
| JP3628999B2 (en) | Anonymous tea and its manufacturing method | |
| CN104922178B (en) | Hypoglycemic effervescent tablet and application thereof | |
| CN115887568A (en) | Traditional Chinese medicine composition for treating liver injury caused by lipid metabolism disorder and preparation method thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| WO2017097167A1 (en) | Zanthoxylum myriacanthum var. pubescens essential oil and application thereof in preparation of drug for treating diabetes | |
| KR20150077794A (en) | Anti-obesity composition comprising herbal extracts as an active ingredient | |
| CN110167570A (en) | For preventing or treating the composition of gastritis or peptic ulcer | |
| Muselin et al. | The use of Yellow Dock (Rumex crispus L.) and Goji Berry (Lycium barbarum L.) in alloxan induced diabetes mellitus in rats | |
| CN107412393B (en) | Preparation method and application of clausena lansium leaf polyphenol extract | |
| CN112603978A (en) | Traditional Chinese medicine composition for treating type 2 diabetes combined with coronary heart disease and preparation method thereof | |
| CN106942439B (en) | Cyclocarya paliurus and guava leaf blood glucose reducing tea and preparation method and application thereof | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| JP2009215253A (en) | Carbohydrate metabolism control substance originated from persimmon leaf and persimmon branch | |
| CN108853184A (en) | A kind of blue or green money willow and Pasania cuspidata extract combination | |
| CN108743840A (en) | A kind of Chinese medicine composition and preparation method thereof with auxiliary lipid-lowering function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230918 Address after: Room 1218-19, Building 3, No. 1366 Hongfeng Road, Huzhou Economic and Technological Development Zone, Huzhou City, Zhejiang Province, 313098 Patentee after: Zhonghe baosang Biotechnology Co.,Ltd. Address before: 810001 No. 59 Xiguan Street, Xining, Qinghai Patentee before: Northwest Institute of Plateau Biology, Chinese Academy of Sciences |